{"url_path":"/sec/ikt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-219641-index.html","accession_number":"0001193125-26-219641","cik":"0001750149","ticker":"IKT","issuer_name":"Inhibikase Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-219641-index.html","primary_entity_key":"0001750149","primary_entity_name":"Inhibikase Therapeutics, Inc."},"word_count":385,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nIncorporated by Reference to SEC Filing\n\nExhibit\nNo.\n\nFiled Exhibit Description\n\nForm\n\nExhibit\nNo.\n\nFile No.\n\nDate Filed\n\n  3.1\n\n[Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1750149/000110465920140170/tm2039446d1_ex3-1.htm)\n\n8-K\n\n3.1\n\n001-39676\n\n12/29/2020\n\n3.2\n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1750149/000119312523178328/d517782dex31.htm)\n\n8-K\n\n3.1\n\n001-39676\n\n06/29/2023\n\n3.3\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/d909904dex31.htm)\n\n \n\n8-K\n\n \n\n3.1\n\n \n\n001-39676\n\n \n\n01/06/2025\n\n3.4\n\n \n\n[Amended and Restated Bylaws of Inhibikase Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1750149/000110465920140170/tm2039446d1_ex3-2.htm)\n\n \n\n8-K\n\n \n\n3.2\n\n \n\n001-39676\n\n \n\n12/29/2020\n\n4.1\n\n \n\n[Specimen common stock certificate of the Registrant](https://www.sec.gov/Archives/edgar/data/1750149/000110465920085909/tm2024520d2_ex4-1.htm)\n\n \n\nS-1\n\n \n\n4.1\n\n \n\n333-240036\n\n \n\n07/23/2020\n\n  31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ikt-ex31_1.htm)\n\n  31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ikt-ex31_2.htm)\n\n  32.1**\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ikt-ex32_1.htm)\n\n  32.2**\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ikt-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n(*) Filed herewith.\n\n(**) Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.\n\n30\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nInhibikase Therapeutics, Inc.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Mark Iwicki\n\nMark Iwicki\n\nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n\nDate: May 12, 2026\n\n \n\nBy:\n\n/s/ David McIntyre\n\nDavid McIntyre\n\nChief Financial Officer\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n \n\n31"}